Lung Cancer Research Foundation and Oncology Advocates United for Climate and Health – International Announce Request for Proposals Now Open for Submission
“NEW YORK, Jan. 12, 2026 /PRNewswire/ — The Lung Cancer Research Foundation (LCRF) and Oncology Advocates United for Climate and Health – International (OUCH-I) announce today that their collaborative research program, titled OUCH-International and LCRF Research Grant Program on the Effects of Air Pollution and Climate Change on Carcinogenesis and Lung Cancer Prevalence, is now accepting proposals. The two organizations are partnering to fund projects that examine the impact of environmental pollution and climate change on lung cancer risk, diagnosis, treatment and outcomes; along with innovative strategies to mitigate these effects. With support from AstraZeneca, the selected project will receive a $200,000 award over a two-year period.”
Lung Cancer Research Foundation Announces 2026 Requests for Proposals
“NEW YORK, Jan. 12, 2026 /PRNewswire/ — The Lung Cancer Research Foundation (LCRF) announced today that its 2026 funding opportunities are officially open for applications.”
FDA Receives BLA for Ivonescimab Plus Chemo in Second-Line or Later EGFR-Mutant NSCLC
“Key Takeaways: Ivonescimab combined with chemotherapy showed improved progression-free survival in EGFR-mutated NSCLC patients post-EGFR TKI treatment, meeting the primary endpoint in the HARMONi trial. The HARMONi trial’s secondary endpoints included overall response rate, duration of response, and safety, with ivonescimab showing favorable outcomes.”
KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors
“Given the limited survival benefit associated with KRAS-targeted therapies and rapid emergence of resistance in clinical settings, our findings establish ERBB/AURK co-inhibition as a promising therapeutic strategy to improve durability of response and combat acquired resistance in KRAS driven LUAD.”
Predictors and latent class associations with lung cancer screening intentions
“Conclusions: Factors associated with LCS intentions highlight opportunities to expand screening. Attending to content for Hispanic adults, increasing discussions of LCS by health care providers, and tailoring communications to incorporate cancer worry could increase use of this life-saving intervention.”
Pennsylvania, New Jersey, Delaware each have improving lung cancer survival rates, new report says
“Significant progress is being made in the fight against lung cancer, according to a new study from the American Lung Association. But more work needs to be done. A state-by-state analysis says Pennsylvania, New Jersey and Delaware are at or above the national average for survival, detection and treatment.”
FDA approves crucial new indication for Imfinzi
“The US Food and Drug Administration on Friday approved immuno-oncology drug Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).”
Study: ADRIATIC clinical trial results suggest durvalumab may offer a new path in small cell lung cancer care
“MIAMI, FLORIDA (Jan. 9, 2026) – A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC). However, its cost raises questions about sustainability, prevention and access.”
Lung cancer risk rises with this common “eco‑friendly” heating method, scientists warn
“Roughly seven million French households rely on wood for heating, long seen as a green and affordable option. But a major study has revealed a hidden danger: women exposed to wood smoke have a 43% higher chance of developing lung cancer. This silent threat may be lingering in our living rooms.”
Veteran San Francisco firefighter denied cancer treatment by insurance
“A retired San Francisco firefighter and his family are pleading with San Francisco officials to intervene in what they describe as a matter of life and death. Ken Jones, who spent 17 years as a firefighter in the city, suffers from an advanced stage of lung cancer, known as adenocarcinoma. Jones’s oncologists at UCSF say he needs a specific course of treatment involving chemo and immunotherapies, but his city employee insurance plan, run by Blue Shield of California, denied the coverage last month and the subsequent appeal filed by Jones’s physicians. The family tells NBC Bay Area despite the urging from Jones’s doctors, the insurance company denied the claim and described the proposed treatment as being outside the standard course of care.”
Immunotherapy before and after surgery improved outcomes in lung cancer patients with lymph node metastases
“Perioperative nivolumab plus neoadjuvant chemotherapy improved outcomes for patients regardless of whether their cancer had spread to their lymph nodes. These findings suggest that N2 status may not be as limiting for treatment as previously thought and support a paradigm shift toward combined chemotherapy plus immunotherapy.”
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
“REDWOOD CITY, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to zoldonrasib, a RAS(ON) G12D-selective inhibitor, for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic NSCLC who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy.”
New Research May Reveal Why Lung Cancer and COPD Overlap
“After years of working with patients living with lung disease as a pulmonologist, Catherine Rufatto Sears, MD, of Indiana University understands the devastating impact of lung cancer and chronic obstructive pulmonary disease (COPD). As a physician scientist, she focuses her research on uncovering new clues about how these diseases interact, why they often occur together and how we may one day prevent them.”
Global study explores lung cancer risk among never-smokers
“While avoiding cigarettes and tobacco can help prevent lung cancer, rising rates of diagnosis among those who’ve never smoked are raising questions about other risk factors for the disease. Professor Emeritus of Epidemiology Martin Tammemägi is closely monitoring the global trend as co-leader of the FALCONS study, an international network of researchers investigating lung cancer risk factors among never-smoking individuals. The disease is currently the fifth-highest cause of cancer deaths worldwide.”
Financial Factors Affect Cancer Patients’ Enrollment in Clinical Trials
“Having an annual income greater than $68,000 was associated with approximately 67% greater odds of trial enrollment.”
